These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


294 related items for PubMed ID: 15190257

  • 1. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M.
    Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
    [Abstract] [Full Text] [Related]

  • 2. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
    Satou Y, Matsuoka M.
    Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
    [Abstract] [Full Text] [Related]

  • 3. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
    Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Bex F, de Thé H, Hermine O, Bazarbachi A.
    Oncogene; 2005 Jan 13; 24(3):419-30. PubMed ID: 15543232
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
    Tan C, Waldmann TA.
    Cancer Res; 2002 Feb 15; 62(4):1083-6. PubMed ID: 11861386
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ.
    Clin Cancer Res; 2003 Oct 01; 9(12):4570-7. PubMed ID: 14555532
    [Abstract] [Full Text] [Related]

  • 9. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
    Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C.
    Clin Cancer Res; 2001 May 01; 7(5):1419-28. PubMed ID: 11350913
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K.
    Int J Oncol; 2011 Dec 01; 39(6):1529-36. PubMed ID: 21785822
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
    Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, Watanabe T, Umezawa K, Urano T.
    Carcinogenesis; 2005 Aug 01; 26(8):1382-8. PubMed ID: 15831528
    [Abstract] [Full Text] [Related]

  • 13. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB.
    Clin Cancer Res; 2003 Oct 01; 9(12):4537-45. PubMed ID: 14555528
    [Abstract] [Full Text] [Related]

  • 14. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A.
    Clin Cancer Res; 2004 May 01; 10(9):3207-15. PubMed ID: 15131062
    [Abstract] [Full Text] [Related]

  • 15. [Proteasome inhibitors].
    Hatake K, Mishima Y, Terui Y.
    Gan To Kagaku Ryoho; 2004 Jul 01; 31(7):999-1002. PubMed ID: 15272575
    [Abstract] [Full Text] [Related]

  • 16. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y, Rahmani M, Grant S.
    Oncogene; 2003 Oct 16; 22(46):7108-22. PubMed ID: 14562039
    [Abstract] [Full Text] [Related]

  • 17. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
    Abou-Merhi R, Khoriaty R, Arnoult D, El Hajj H, Dbouk H, Munier S, El-Sabban ME, Hermine O, Gessain A, de Thé H, Mahieux R, Bazarbachi A.
    Leukemia; 2007 Aug 16; 21(8):1792-801. PubMed ID: 17568816
    [Abstract] [Full Text] [Related]

  • 18. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM, Tepper JE, Baldwin AS, Liu R, Adams J, Elliott P, Cusack JC.
    Int J Radiat Oncol Biol Phys; 2001 May 01; 50(1):183-93. PubMed ID: 11316563
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.